US9850229 — Compounds and compositions as protein kinase inhibitors
Method of Use · Assigned to Array Biopharma Inc · Expires 2030-08-27 · 4y remaining
What this patent protects
This patent protects a novel class of compounds used to treat or prevent diseases associated with abnormal B-Raf activation.
USPTO Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Drugs covered by this patent
- Mektovi (binimetinib) · Pfizer
- Braftovi (encorafenib) · Pfizer
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2333 |
— | Mektovi |
U-2337 |
— | Braftovi |
U-2337 |
— | Braftovi |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.